MENU

FDA advisors recommend Pfizer’s RSV vaccine for infants but raise safety concerns

The FDA is slated to make a decision on whether to approve Pfizer's shot in August before respiratory syncytial virus season in the fall.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story